The global Apheresis Market is entering a high-growth phase, driven by rising demand for blood components, expanding applications in chronic and autoimmune disorders, and accelerating innovation in automated apheresis systems. According to Market Research Future (MRFR), the market size—valued at USD 1.2 billion in 2024—is projected to reach USD 3.097 billion by 2035, registering a robust 9.0% CAGR during 2025–2035.
For B2B stakeholders across hospitals, medical device manufacturers, biotechnology firms, and blood donation networks, apheresis is becoming an integral enabler of advanced therapeutic care and blood component optimization.
Market Overview: Rising Demand for Precision Blood Component Therapy
Apheresis, the process of selectively separating blood components, is witnessing increased adoption across:
Therapeutic Apheresis for autoimmune disorders
Donor Apheresis for platelets, plasma, and red cell collection
Plasma Apheresis to meet rising demand for immunoglobulins
Cell Apheresis for oncology, stem cell therapy, and CAR-T workflows
Key factors influencing growth include:
Increasing prevalence of chronic diseases, cancers, and immune disorders
Rising demand for plasma-derived medicinal products (PDMPs)
Advancements in automation, safety technology, and digital integration
Expansion of blood donation programs globally
Supportive regulatory and reimbursement frameworks
Key Trends Shaping the Apheresis Market
1. Rapid Shift Toward Automated Apheresis Systems
Hospitals and blood centers are replacing manual processes with next-generation automated apheresis devices that offer:
Higher throughput
Real-time monitoring
Enhanced donor safety
Standardized component collection
Companies like Terumo, Haemonetics, and Fresenius Kabi are integrating analytics, AI, and digital platforms to streamline workflow efficiency.
2. Growing Adoption of Plasma Apheresis Driven by Plasma Derivatives
Demand for immunoglobulins, clotting factors, and albumin is increasing at an unprecedented rate. Plasma apheresis plays a critical role in meeting this demand, supporting growth across:
Biotechnology companies
Fractionation facilities
Blood collection organizations
3. Rising Need for Therapeutic Apheresis in Chronic & Autoimmune Disorders
Therapeutic apheresis remains the largest market segment, supported by treatment applications in:
Myasthenia gravis
Guillain-Barré syndrome
Rheumatoid arthritis
Certain cancers
Renal and neurological disorders
This segment represents the strongest revenue driver across hospitals globally.
4. Sustainability and Digitalization in Blood Management
Major players are investing in:
Energy-efficient devices
Predictive analytics
Digital donor management systems
Traceability platforms for compliance
These advancements are strengthening value-chain transparency and operational excellence.
Market Segmentation Insights
✔ By Product Type
Therapeutic Apheresis (Largest Segment)
Donor Apheresis (Fastest-Growing)
Plasma Apheresis
Cell Apheresis
Therapeutic Apheresis leads due to rising use in cancer and autoimmune therapies, while Donor Apheresis grows rapidly as global plasma demand surges.
✔ By Application
Cancer Treatment (Largest)
Autoimmune Disorders (Fastest-Growing)
Neurological Disorders
Renal Disorders
Cancer therapy continues to dominate, but autoimmune applications show multi-fold growth due to increased diagnostics and treatment expansion.
✔ By End User
Hospitals (Dominant)
Blood Donation Centers (Fastest-Growing)
Research Laboratories
Hospitals lead consumption, while blood centers rapidly adopt automated donor collection systems.
✔ By Procedure Type
Automated Apheresis (Largest)
Manual Apheresis (Emerging for low-resource settings)
Automation is expected to capture the highest valuation by 2035.
Regional Outlook
North America – Market Leader (≈45% share)
Explore the full report here:https://www.marketresearchfuture.com/reports/apheresis-market/companies
Driven by:
High therapeutic apheresis adoption
Strong presence of key players like Haemonetics & Fresenius Kabi
Advanced healthcare infrastructure
Europe – Strong Growth Potential (≈30% share)
Countries such as Germany, France, UK are driving demand through enhanced blood donation policies and advanced medical technologies.
Asia-Pacific – Fastest-Growing Region (≈20% share)
Growth supported by:
Rising chronic disease burden
Healthcare modernization
Large donor base
China and Japan dominate the regional market.
Middle East & Africa – Emerging Opportunity (≈5% share)
Improving healthcare infrastructure and rising awareness are opening new B2B opportunities for device manufacturers.
Competitive Landscape: Innovation & Partnerships Accelerate Growth
Leading companies include:
Terumo, Fresenius Kabi, Haemonetics, Grifols, Octapharma, Asahi Kasei, Cellerant, Blood Centers of America, Kedrion
Recent industry developments:
Fresenius Kabi partners with Mayo Clinic on therapeutic apheresis R&D (2025)
Haemonetics launches advanced digital donor management platform
Grifols expands manufacturing capabilities for PDMPs
Terumo BCT invests USD 100M in next-gen device R&D
Strategic moves reflect a shift toward digital transformation, AI integration, and supply-chain expansion.
Future Outlook: Apheresis Market Poised for High-Value Growth
By 2035, the global Apheresis Market will witness strong adoption driven by:
Increased use of automated, AI-enabled apheresis systems
Expansion of outpatient therapeutic apheresis services
High demand for plasma derivatives and cell-based therapies
Strategic partnerships between hospitals and biotech companies
The market is expected to surpass USD 3.09 Billion, establishing apheresis as a core pillar of modern therapeutic and donor-driven care.
